ResearcherCapital Medical UniversityNo recent work listed
Guangyu An
Matched on ORCID iD 0000-0003-1597-5188; OpenAlex author ID A5101412280. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 18
2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 1 paper
Papers 5
- Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.tranon.2021.101317↗
- Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer. Last author DOI 10.1016/j.lfs.2019.117150↗
- Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cance… Co-author DOI 10.1155/2019/6402925↗
- Short-term clinical outcomes of enteral nutrition versus parenteral nutrition after surgery for pancreatic cancer: a meta-analysis. Last author DOI 10.21037/tcr.2019.07.47↗
- Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. Co-author DOI 10.1371/journal.pone.0118933↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yang Ge · 3 shared papers, 2019–2022 · strength 0.41
- Paper Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal… DOI 10.1016/j.tranon.2021.101317↗
- Paper Short-term clinical outcomes of enteral nutrition versus parenteral nutrition after surgery for pancreatic cancer: a me… DOI 10.21037/tcr.2019.07.47↗
- Paper Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer. DOI 10.1016/j.lfs.2019.117150↗
- Rui Yan · 2 shared papers, 2020–2022 · strength 0.28
- Xiaona Fan · 1 shared paper, 2022 · strength 0.16
- Yuanyuan Zhang · 1 shared paper, 2022 · strength 0.16
- Yi‐Kun Kang · 1 shared paper, 2019 · strength 0.14
- Dong Li · 1 shared paper, 2019 · strength 0.14
- Nathaniel Weygant · 2 shared papers, 2015–2019 · strength 0.12
- Paper Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to I… DOI 10.1155/2019/6402925↗
- Paper Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circul… DOI 10.1371/journal.pone.0118933↗
- Ben Z. Stanger · 2 shared papers, 2015–2019 · strength 0.12
- Paper Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to I… DOI 10.1155/2019/6402925↗
- Paper Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circul… DOI 10.1371/journal.pone.0118933↗
- Courtney W. Houchen · 2 shared papers, 2015–2019 · strength 0.12
- Paper Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to I… DOI 10.1155/2019/6402925↗
- Paper Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circul… DOI 10.1371/journal.pone.0118933↗
- Dongfeng Qu · 2 shared papers, 2015–2019 · strength 0.12
- Paper Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to I… DOI 10.1155/2019/6402925↗
- Paper Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circul… DOI 10.1371/journal.pone.0118933↗
- Min Li · 1 shared paper, 2019 · strength 0.08
- Timothy Cragin Wang · 1 shared paper, 2019 · strength 0.08
- Sripathi M. Sureban · 1 shared paper, 2015 · strength 0.04
- James Randolph Sanders Hocker · 1 shared paper, 2015 · strength 0.04
- Nicole M. Aiello · 1 shared paper, 2015 · strength 0.04
- Jay S. Hanas · 1 shared paper, 2015 · strength 0.04
- Andrew D. Rhim · 1 shared paper, 2015 · strength 0.04
- Shubham Pant · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.